Trial Profile
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RTA 1701 in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs RTA 1701 (Primary)
- Indications Autoimmune disorders; Inflammation
- Focus Adverse reactions; First in man
- Sponsors Biogen
- 02 Jul 2019 Status changed from recruiting to completed.
- 20 Jun 2018 According to a Reata Pharmaceuticals media release, initial results are expected in the first half of 2019.
- 20 Jun 2018 Status changed from planning to recruiting, according to a Reata Pharmaceuticals media release.